Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC)
Eric Van Cutsem(Roche (Switzerland)), Yoon‐Koo Kang(Roche (Switzerland)), Hyun Cheol Chung(Roche (Switzerland)), Akira Sawaki(Roche (Switzerland)), Florian Lordick(Roche (Switzerland)), Julie Hill(Roche (Switzerland)), Michaela Lehle(Roche (Switzerland)), A. Feyereislova(Roche (Switzerland)), Yung‐Jue Bang(Roche (Switzerland))
Cited by 204
Abstract
LBA4509 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. [Table: see text]
Related Papers
No related papers found
Powered by citation graph analysis